HUMAN IGG1 LAMBDA MONOCLONAL ANTIBODY AGAINST ALFA-SYNUCLEIN, SALINE, HUMAN IGG1 LAMBDA MONOCLONAL ANTIBODY AGAINST ALFA-SYNUCLEIN
TAK-341-2001
Phase 2 small_molecule active
Quick answer
HUMAN IGG1 LAMBDA MONOCLONAL ANTIBODY AGAINST ALFA-SYNUCLEIN, SALINE, HUMAN IGG1 LAMBDA MONOCLONAL ANTIBODY AGAINST ALFA-SYNUCLEIN for Multiple System Atrophy is a Phase 2 program (small_molecule) at Takeda Pharmaceuticals International AG with 1 ClinicalTrials.gov record(s).
Program details
- Company
- Takeda Pharmaceuticals International AG
- Indication
- Multiple System Atrophy
- Phase
- Phase 2
- Modality
- small_molecule
- Status
- active